minneapolis, mn register registration deadline: july 12, 2025 save the date quality care symposium oct 10 - oct 12, 2025 online & in-person | chicago, il subscribe for updates arrow_back_ios arrow_forward_ios most viewed text_snippet videos & slides 2023 asco annual meeting phase ii trial...
●3.注册费用:因是否为 ASCO 会员、现场/线上参会形式而异(详情请看:https://conferences.asco.org/am/registration)。 ●4. 在线参会:若因其他日程安排缘由等无法前往现场与会,您还可以选择线上参会,全程直播、会后回放均可看 (线上直播链接: https...
(线上直播链接: https://meetings.asco.org/meetings/2024-asco-annual-meeting/316/program-guide/scheduled-sessions)。 此外,注册后,您在会后 3 年内将享有查阅和下载会议的全部独家资料内容的权限。 Tips: 1. 注册、更正、取消参会及费用详情链接如下: https://conferences.asco.org/am/registration 2. 如果...
The Best of ASCO®2024 Vancouver faculty will draw from some of Western Canada’s most influential oncologists. Learning Objectives Summarize the most significant treatment advances presented at the 2024 ASCO®Annual Meeting. Describe the current standard of care for key malignancies. Discuss the c...
癌症研究正处于快速发展的黄金时期,6月初,备受瞩目的美国临床肿瘤学会年会(ASCO Annual Meeting)在芝加哥成功落下帷幕。作为肿瘤学领域最顶尖的学术盛会,ASCO年会给学界带来了丰富的肿瘤学知识和深刻洞见。本次ASCO年会上,中国学者和研究表现亮眼——近400篇...
ASCO has announced that the 2021 ASCO Annual Meeting will be an online-only experience, taking place from June 4 to 8, 2021. The Society issued the following statement on the Meeting: We had hoped for a return to an in-person meeting, as we all miss the opportunity to see and engage ...
REGISTRATION Annual Meeting Registration $110.00 REGISTRATION OPTIONS ASCO Annual Business Meeting (ASCO Members Only) Date: 06/05/17 Time: 12:00PM-1:00PM No Charge Payment Information Payment Type: CCD Payment Reference: VISA 4xxx1243 Exp: 07/21 ...
Merck investor event Merck will hold an Oncology Investor Event to coincide with the 2024 ASCO Annual Meeting on Monday, June 3, 2024, 6 p.m. CT, at which senior management will provide an update on the company’s oncology st...
The clinical and safety data from Cohort 1A continue to reinforce the rationale for the TILVANCE-301 trial.TILVANCE-301is a global, randomized, registrational Phase 3 trial to support accelerated and fullU.S.approvals of lifileucel in combination with pembrolizumab in frontline advance...
The new drug application for fulzerasib monotherapy in treating advanced KRAS G12C-mutant NSCLC has been accepted and granted priority review designation by China's National Medical Products Administration (NMPA). Based on the data presented at 2023 ESMO Asia, the registrational phase II study of...